Cereno Scientific reports acquired warrants within the framework of the incentive program resolved at the Annual General Meeting
Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that members of the Company’s management have acquired warrants within the framework of the Company’s incentive program as resolved at the Annual General Meeting held on April 16, 2024.The Annual General Meeting of the Company held on April 16, 2024, resolved on a directed issue of warrants of series 2024/2027:1 to current employees of the Company’s management within the framework of an incentive program. The